The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
FACULTY
Ryan Jacobs, MD (PROGRAM CHAIR)
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
PROGRAM OVERVIEW
This case-based enduring activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
TARGET AUDIENCE
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
- Differentiate therapy for the treatment of newly diagnosed or relapsed/ refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
- Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Ryan Jacobs, MD reports that he serves as a consultant for AstraZeneca, Secura Bio, Genentech, Adaptive, and TG Therapeutics. He also serves on speakers’ bureaus for Pharmacyclics, Janssen, AbbVie, TG Therapeutics, Secura Bio and AstraZeneca. Dr. Jacobs has also completed contracted research for Pharmacyclics, Teneobio, MEI Pharma, and TG Therapeutics.
CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
Teresa L. Keating, MSN, RN, WHNP
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose
Staff Planners and Managers
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Teresa L. Keating, MSN, RN, WHNP, UMA/CMM – LNP, has nothing to disclose.
Debra Gordon, Medical Director of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Jessica Feygin, Program Coordinator of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Submit the evaluation form to Med Learning Group.
You will receive your certificate upon completion as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASE DATE: March 04, 2022
EXPIRATION DATE: March 04, 2023
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
